Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10132331 | 0.90 | KCNH2 (0.47) | DRD2SIGMAR1DRD3KCNH2SMN1; SMN2 | |
| SCHEMBL10130902 | 0.90 | KCNH2 (0.47) | DRD2SIGMAR1DRD3KCNH2SMN1; SMN2 | |
| SCHEMBL10132333 | 0.90 | KCNH2 (0.47) | DRD2SIGMAR1DRD3KCNH2SMN1; SMN2 | |
| SCHEMBL10131058 | 0.89 | BMPR1B (0.41) | DRD2SIGMAR1DRD3KCNH2SMN1; SMN2 | |
| SCHEMBL10130858 | 0.88 | KCNH2 (0.47) | DRD2SIGMAR1DRD3KCNH2SMN1; SMN2 | |
| SCHEMBL10130859 | 0.88 | KCNH2 (0.47) | DRD2SIGMAR1DRD3KCNH2SMN1; SMN2 | |
| SCHEMBL10130862 | 0.88 | KCNH2 (0.47) | DRD2SIGMAR1DRD3KCNH2SMN1; SMN2 | |
| SCHEMBL10132368 | 0.86 | BMPR1B (0.43) | DRD2DRD3KCNH2NPC1RAB9A | |
| SCHEMBL10132384 | 0.86 | BMPR1B (0.43) | DRD2DRD3KCNH2NPC1RAB9A | |
| SCHEMBL10132390 | 0.86 | BMPR1B (0.43) | DRD2DRD3KCNH2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906913-B2 | Azabicyclohexanes | PANACEA BIOTEC LIMITED (IN) | 2014-12-09 | — | — | US | disclosed |
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD. (IN) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | CYP3A43, UGT1A1, CYP3A4 | DRD2 834/4885SIGMAR1 815/4885DRD3 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.